• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Santhera Pharmaceuticals (USA) Inc.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular and neurodegenerative diseases, an area of high unmet medical need which includes many orphan and niche indications with no current therapy. Santhera's first product, Catena® to treat Friedreich's Ataxia is marketed in Canada. *

 

	Start	2011-04-28 existent
	Group	Santhera (Group)
	Industry	pharmaceutical
	Region	Burlington, MA
	Country	United States (USA)
	City	Burlington, MA
		Address record changed: 2021-11-05
Basic data	Employees	n. a.
		* Document for �About Section�:
		Record changed: 2021-11-05

Advertisement

More documents for Santhera (Group)

• [1] Santhera Pharmaceuticals Holding AG. (1/4/22). "Press Release: Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region". Pratteln....
• [2] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
• [3] Santhera Pharmaceuticals Holding AG. (10/6/20). "Press Release: Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone". Pratteln....
• [4] Santhera Pharmaceuticals Holding AG. (1/24/20). "Press Release: Santhera Appoints New Chief Financial Officer". Pratteln....
• [5] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
• [6] Santhera Pharmaceuticals Holding AG. (12/14/18). "Press Release: Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license". Pratteln....
• [7] Santhera Pharmaceuticals Holding AG. (12/12/18). "Press Release: Santhera Announces Financial Results for the First Nine Months of 2018". Pratteln....
• [8] Santhera Pharmaceuticals Holding AG. (11/21/18). "Press Release: Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone". Pratteln & Allschwil....
• [9] Santhera Pharmaceuticals Holding AG. (11/21/18). "Press Release: Santhera Calls Extraordinary General Meeting and Proposes Ordinary Share Capital Increase to Raise Approximately CHF 50 Million". Pratteln & Allschwil....
• [10] Santhera Pharmaceuticals Holding AG. (1/26/18). "Press Release: Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone in Duchenne Muscular Dystrophy". Liestal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.